Urgent treatment of patients with metastatic melanoma using braf inhibitors in the absence of braf mutation status

By Nathan P.   Sharma A.   Lorigan P.  

Annals of Oncology, Vol. 24, Iss. 6, 2013-06 ,pp. : 1712-1713

Oxford University Press

Access to resources Recommend Favorite

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression

By Eisele Günter   Wick Antje   Eisele Anna-Carina   Clément Paul   Tonn Jörg   Tabatabai Ghazaleh   Ochsenbein Adrian   Schlegel Uwe   Neyns Bart   Krex Dietmar   Simon Matthias   Nikkhah Guido   Picard Martin   Stupp Roger   Wick Wolfgang   Weller Michael  

Journal of Neuro-Oncology, Vol. 117, Iss. 1, 2014-03 ,pp. : 141-145

Springer Publishing Company

Access to resources Recommend Favorite

Implication of Unfolded Protein Response and Autophagy in the Treatment of BRAF Inhibitor Resistant Melanoma

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 16, Iss. 3, 2016-02 ,pp. : 291-298

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment patterns and outcomes in BRAF V600E‐mutant melanoma patients with brain metastases receiving vemurafenib in the real‐world setting

By  

Cancer Medicine, Vol. 4, Iss. 8, 2015-08 ,pp. : 1205-1213

John Wiley & Sons Inc

Access to resources Recommend Favorite

Oblimersen in the treatment of metastatic melanoma

By Tarhini Ahmad A   Kirkwood John M  

Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. : 263-271

Future Medicine

Access to resources Recommend Favorite